{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:31:59Z","timestamp":1782451919547,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":855,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Patients with heart failure (HF) often suffer from a range of comorbidities, which may affect their health status. The aim of this study was to assess the impact of different comorbidities on health status in patients with HF and reduced (HFrEF) and preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Using individual patient data from HFrEF (ATMOSPHERE, PARADIGM-HF, DAPA-HF) and HFpEF (TOPCAT, PARAGON-HF) trials, we examined the Kansas City Cardiomyopathy Questionnaire (KCCQ) domain scores and overall summary score (KCCQ-OSS) across a range of cardiorespiratory (angina, atrial fibrillation [AF], stroke, chronic obstructive pulmonary disease [COPD]) and other comorbidities (obesity, diabetes, chronic kidney disease [CKD], anaemia). Of patients with HFrEF (n\u2009=\u200920\u2009159), 36.2% had AF, 33.9% CKD, 33.9% diabetes, 31.4% obesity, 25.5% angina, 12.2% COPD, 8.4% stroke, and 4.4% anaemia; the corresponding proportions in HFpEF (n\u2009=\u20096563) were: 54.0% AF, 48.7% CKD, 43.4% diabetes, 53.3% obesity, 28.6% angina, 14.7% COPD, 10.2% stroke, and 6.5% anaemia. HFpEF patients had lower KCCQ domain scores and KCCQ-OSS (67.8 vs. 71.3) than HFrEF patients. Physical limitations, social limitations and quality of life domains were reduced more than symptom frequency and symptom burden domains. In both HFrEF and HFpEF, COPD, angina, anaemia, and obesity were associated with the lowest scores. An increasing number of comorbidities was associated with decreasing scores (e.g. KCCQ-OSS 0 vs. \u22654 comorbidities: HFrEF 76.8 vs. 66.4; HFpEF 73.7 vs. 65.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cardiac and non-cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype. Treating\/correcting comorbidity is a therapeutic approach that may improve the health status of patients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2962","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:56:41Z","timestamp":1688446601000},"page":"1606-1618","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction"],"prefix":"10.1093","volume":"25","author":[{"given":"Mingming","family":"Yang","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kondo","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Adamson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad H.","family":"Butt","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Copenhagen University Hospital Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Abraham","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, The Ohio State University , Columbus, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karola S.","family":"Jering","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City , Kansas City, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Institut de Cardiologie de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"2026010913101102000_ejhf2962-bib-0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0002","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1795","article-title":"The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial \u2013 Insights from ASCEND-HF","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0003","article-title":"Comprehensive characterization of non-cardiac comorbidities in acute heart failure \u2013 An analysis of ESC-HFA EORP Heart Failure Long-Term Registry","author":"Chioncel","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijcard.2015.05.180","article-title":"Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis","volume":"196","author":"Rushton","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ehf2.13227","article-title":"The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction","volume":"8","author":"Benes","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0006","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"2026010913101102000_ejhf2962-bib-0007","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913101102000_ejhf2962-bib-0008","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010913101102000_ejhf2962-bib-0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: Rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913101102000_ejhf2962-bib-0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026010913101102000_ejhf2962-bib-0012","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0013","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0014","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1818","article-title":"Trends in prevalence of comorbidities in heart failure clinical trials","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00392-022-02076-1","article-title":"Comorbidities complicating heart failure: Changes over the last 15\u2009years","volume":"112","author":"Screever","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0016","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11606-022-07697-w","article-title":"Co-morbidity and polypharmacy burden among adults with self-reported heart failure overall, and by gender and race\/ethnicity: NHANES 2007-2018","volume":"38","author":"Zheutlin","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2026010913101102000_ejhf2962-bib-0017","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-021-00512-3","article-title":"Update on the impact of comorbidities on the efficacy and safety of heart failure medications","volume":"18","author":"Chow","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"2026010913101102000_ejhf2962-bib-0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2083","article-title":"Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: An analysis of DAPA-HF","volume":"23","author":"Dewan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2022.06.004","article-title":"Metabolic disorders as growing risk factors and comorbidities in heart failure","volume":"364","author":"Shang","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0020","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X16666201113093548","article-title":"Common comorbidities that alter heart failure prognosis \u2013 Shaping new thinking for practice","volume":"17","author":"Iyngkaran","year":"2021","journal-title":"Curr Cardiol Rev"},{"key":"2026010913101102000_ejhf2962-bib-0021","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: New insights and pathophysiologic targets","volume":"118","author":"Borlaug","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026010913101102000_ejhf2962-bib-0022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2022.02.037","article-title":"Twenty-year trends in heart failure among U.S. adults, 1999-2018: The growing impact of obesity and diabetes","volume":"362","author":"Ciardullo","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0023","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: The DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913101102000_ejhf2962-bib-0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008837","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: Insights from the DAPA-HF trial","volume":"14","author":"Butt","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0025","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1513\/AnnalsATS.202202-152ED","article-title":"Comorbid chronic obstructive pulmonary disease and heart failure: Shared risk factors and opportunities to improve outcomes","volume":"19","author":"Khan","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026010913101102000_ejhf2962-bib-0026","first-page":"171","article-title":"Chronic obstructive pulmonary disease and heart failure: A breathless conspiracy","volume":"40","author":"Pellicori","year":"2022","journal-title":"Cardiol Clin"},{"key":"2026010913101102000_ejhf2962-bib-0027","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021494","article-title":"Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: Insights from PARAGON-HF","volume":"10","author":"Mooney","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913101102000_ejhf2962-bib-0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008052","article-title":"Cardiac and noncardiac disease burden and treatment effect of sacubitril\/valsartan: Insights from a combined PARAGON-HF and PARADIGM-HF analysis","volume":"14","author":"Rohde","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019238","article-title":"Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: Insights from PARADIGM-HF","volume":"10","author":"Ehteshami-Afshar","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913101102000_ejhf2962-bib-0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: Findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0031","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ejhf.2393","article-title":"Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: Findings from the BIOSTAT-CHF study","volume":"24","author":"Alnuwaysir","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0032","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"2026010913101102000_ejhf2962-bib-0033","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/ejhf.1762","article-title":"Patient-reported outcomes for heart failure with preserved ejection fraction: Conducting quality studies on quality of life","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0034","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jchf.2019.06.006","article-title":"Patient-reported outcomes: The future of heart failure care","volume":"7","author":"Heidenreich","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0036","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913101102000_ejhf2962-bib-0037","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913101102000_ejhf2962-bib-0038","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026010913101102000_ejhf2962-bib-0039","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","article-title":"The persistent exclusion of older patients from ongoing clinical trials regarding heart failure","volume":"171","author":"Cherubini","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026010913101102000_ejhf2962-bib-0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1606\/65559747\/eurjhf_25_9_1606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1606\/65559747\/eurjhf_25_9_1606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:12:33Z","timestamp":1767982353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/9\/1606\/8341870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,3]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2962","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"2023-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}